AstraZeneca announced positive “high-level” results from a global Phase 3 study of gefurulimab, a once-weekly, self-administered complement C5 inhibitor, in adults with generalized myasthenia gravis (MG) positive for anti-acetylcholine receptor antibodies. The drug met its primary and all secondary endpoints with a statistically significant improvement in patient-reported functional scores at 26 weeks compared to placebo. This data positions gefurulimab as a potentially more convenient alternative to current infused therapies for MG.